Shannon Puhalla
Shannon Puhalla
Medical Oncology, University of Pittsburgh
Verified email at upmc.edu
Title
Cited by
Cited by
Year
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas
S Kummar, J Ji, R Morgan, HJ Lenz, SL Puhalla, CP Belani, DR Gandara, ...
Clinical Cancer Research 18 (6), 1726-1734, 2012
1942012
Sensitive detection of mono-and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients
P Wang, A Bahreini, R Gyanchandani, PC Lucas, RJ Hartmaier, ...
Clinical cancer research 22 (5), 1130-1137, 2016
1532016
Prediction of the Onco type DX recurrence score: use of pathology-generated equations derived by linear regression analysis
ME Klein, DJ Dabbs, Y Shuai, AM Brufsky, R Jankowitz, SL Puhalla, ...
Modern Pathology 26 (5), 658-664, 2013
1502013
Translational breast cancer research consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2–positive breast cancer and …
RA Freedman, RS Gelman, JS Wefel, ME Melisko, KR Hess, RM Connolly, ...
Journal of Clinical Oncology 34 (9), 945, 2016
1172016
TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases
RA Freedman, RS Gelman, CK Anders, ME Melisko, HA Parsons, ...
Journal of Clinical Oncology 37 (13), 1081, 2019
1122019
Intrinsic subtype switching and acquired ERBB2/HER2 amplifications and mutations in breast cancer brain metastases
N Priedigkeit, RJ Hartmaier, Y Chen, D Vareslija, A Basudan, RJ Watters, ...
JAMA oncology 3 (5), 666-671, 2017
952017
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized …
HS Han, V Diéras, M Robson, M Palácová, PK Marcom, A Jager, ...
Annals of Oncology 29 (1), 154-161, 2018
922018
Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast …
S Puhalla, JH Beumer, S Pahuja, LJ Appleman, HAH Tawbi, RG Stoller, ...
Journal of Clinical Oncology 32 (15_suppl), 2570-2570, 2014
702014
Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast …
S Puhalla, JH Beumer, S Pahuja, LJ Appleman, HAH Tawbi, RG Stoller, ...
Journal of Clinical Oncology 32 (15_suppl), 2570-2570, 2014
702014
PARP inhibitors in breast cancer: BRCA and beyond
J Rios, S Puhalla
Oncology 25 (11), 1014, 2011
692011
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
S Johnston, S Puhalla, D Wheatley, A Ring, P Barry, C Holcombe, ...
682019
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models
A Bahreini, Z Li, P Wang, KM Levine, N Tasdemir, L Cao, HM Weir, ...
Breast Cancer Research 19 (1), 1-10, 2017
662017
PARP inhibitors in breast cancer: BRCA and beyond
J Rios, S Puhalla
Oncology 25 (11), 1014, 2011
642011
Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer
S Wilks, S Puhalla, J O'Shaughnessy, L Schwartzberg, E Berrak, J Song, ...
Clinical breast cancer 14 (6), 405-412, 2014
632014
Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer
S Wilks, S Puhalla, J O'Shaughnessy, L Schwartzberg, E Berrak, J Song, ...
Clinical breast cancer 14 (6), 405-412, 2014
632014
BRCA 1/2-mutation related and sporadic breast and ovarian cancers: more alike than different
MA Burgess, SL Puhalla
Frontiers in oncology 4, 19, 2014
632014
Hormonal therapy in breast cancer: a model disease for the personalization of cancer care
S Puhalla, S Bhattacharya, NE Davidson
Molecular oncology 6 (2), 222-236, 2012
592012
Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-α–refractory adult T-cell leukemia
A Mone, S Puhalla, S Whitman, RA Baiocchi, J Cruz, T Vukosavljevic, ...
Blood 106 (10), 3380-3382, 2005
542005
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
RJ Hartmaier, SE Trabucco, N Priedigkeit, JH Chung, CA Parachoniak, ...
Annals of Oncology 29 (4), 872-880, 2018
512018
Unsanctifying the sanctuary: challenges and opportunities with brain metastases
S Puhalla, W Elmquist, D Freyer, L Kleinberg, C Adkins, P Lockman, ...
Neuro-oncology 17 (5), 639-651, 2015
452015
The system can't perform the operation now. Try again later.
Articles 1–20